Just like your skin, your hair also needs pampering to look good. For lustrous and long tresses, you need to provide your scalp and hair follicles with the essential nutrients including vitamins, minerals, and proteins. Though there are various supplements available in the market that can stimulate your hair growth, if you wish to go natural, there is a plethora of food items that can give you the same benefit. Read further to know about foods that can promote hair growth. Also Read - Want to Promote Hair Growth And Relieve Insomnia? Opt For Spikenard Essential Oil

Being rich in procyanidin B-2, apples can stimulate epithelial cells and promote hair growth. Also, the antioxidants present in this fruit can fight against the free radicals and reduce hair damage. Even if you wish to improve your hair thickness, you can have apples as they are packed with protein. Also Read - Potential stem cell therapy may help promote hair growth

Strawberries contain vitamin C and other strong antioxidants, that can improve the health of your hair. If anecdotal evidences are to be believed, silica present in strawberries can stop hair loss and prevent the onset of baldness. Eating strawberries every day can treat dandruff and also make your hair appear shiny. Also Read - Top 5 essential oils for hair growth and how to use them

Bananas can help in hair growth by preventing dandruff and improving the quality of your scalp. Its rich nutritional content can also unclog the scalp pores. If you want your hair to impart shine, have a banana every day. It can also prevent breakage and split-ends.

More here:
Best Hair Growth Tips: 5 Food Items to Include in Your Daily Diet For Long And Strong Tresses - India.com

Recommendation and review posted by Bethany Smith

Unfortunate news for those hoping the coronavirus pandemic was fading away: models suggest that an apocalyptic resurgence could be coming in the near future.

Multiple U.S. states, including Florida, Texas, and California, are currently experiencing record daily numbers of new COVID-19 cases, CNN reports. And they all still seem to be on the upswing.

Dr. Peter Hotez, dean of Baylor College of Medicines National School of Tropical Medicine, told CNN that Houston is on track to be the most coronavirus-ravaged city in the U.S. but that other Texas cities arent far behind.

The big metro areas seem to be rising very quickly and some of the models are on the verge of being apocalyptic, Hotez told CNN.

The three states hitting record numbers right now are also the most populous in the country. Combined, their new surges put more than 27 percent of the U.S. population at risk, CNN reports.

Hotez, whos also working on an experimental COVID-19 vaccine, warns that Houston in particular may quadruple its coronavirus case load over the next two weeks, which would put the same devastating strain on its healthcare system that places like New York City experienced earlier in the year.

That is really worrisome and as those numbers rise, were seeing commensurate increases in the number of hospitalizations and ICU admissions, Hotex told CNN. You get to the point where you overwhelm ICUs and thats when the mortality goes up.

Read more from the original source:
Professor: Looming COVID Surge on "Verge of Being Apocalyptic" - Futurism

Recommendation and review posted by Bethany Smith

In an interview with CURE, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.

BY Ryan McDonald and Dr. Mazyar Shadman

A common mistake that tends to occur when patients are treated for chronic lymphocytic leukemia is the notion that only a patients cells are being treated, according to Dr. Mazyar Shadman.

In an interview with CURE, Shadman, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Center, discussed the enormous variety in treatment preference among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.

Transcription:

The main bulk of my discussion is really what they want. You will be surprised at how different patients are in terms of what's important for them. One side of the spectrum, I have patients who really don't want a treatment that's forever, and that makes sense, right? No matter how safe the drug is, no matter how disease-free you are, just for some patients, just the thought of being on medication forever that's for cancer is important. And they just don't want it; they want to be disease-free, but also treatment-free as long as possible. And so that's important for some patients, and in the appropriate setting, if I feel that, yes, you know, we can go with either chemotherapy-based therapy in this patient or now venetoclax-based therapy (which) is a non-chemotherapy and a time-limited option potentially. For those patients based on that decision, of course, that's what I will provide to them.

I also have patients who really don't (care, and will say) I'm taking four medications for years, four different products, and (if) you give me something, I don't want to deal with the whole rampup and checking MRD, (but) as long as I'm fine,, I'll take it, so that you see both sides, and you do see patients who still come for chemotherapy. So, yes, patient preference is important. Patients need to understand and need to be educated on what to expect. It's always easy to start treatment. We get patients who come back six months, seven months later, and (say) You know what, I'm taking this for seven months it works, but can I stop? I mean, what do you mean (this) is going to go forever? The doctor who started didn't talk to me about (that).

So, I think those conversations are actually very important. And I add one more thing, they're important because we don't have a head-to-head trial that tells me that acalabrutinib or venetoclax which one is better. If I have that, then I probably won't give that option, or if I do, I make sure they understand that they're going for a treatment that's not superior, but we don't have that. So really, you have to sit and present both treatments and pros and cons and have them decide based on what's the best fit for them. And that's why it's important to have really a comprehensive approach to the patient I mean, it's really treating a patient, not the molecular kind of finding in the CLL cell, and that's a common mistake: Oh, I have somebody with a mutated (gene, and) that (means) I give chemo. No: You have a patient who has CLL whose CLL has this (mutation). So, then you kind of look at the patient and not the other factors.

Visit link:
Conversations Between Patient and Oncologist Are Important in Avoiding 'Common Mistake' When Treating CLL - Curetoday.com

Recommendation and review posted by Bethany Smith

Image: Neuroblastoma rosettes. Credit:Dr. Maria Tsokos, National Cancer Institute(Public domain).

A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma a common childhood tumourwith a low survival rate.

Neuroblastoma is a cancer in childrenwhich arises from nerve cells in either the chest or the abdomen. In some neuroblastoma cases there is an abnormal gene called MYCN that makes it particularly difficult to treat.

Currently, children receive intense chemotherapy, radiotherapy and surgery but despite this only about half of children with high-risk neuroblastoma will survive.

Researchers at Sheffield Universitycollaborated with The Institute of Cancer Research, London, to conduct research to find a new, more effective and less toxic way to target high-risk neuroblastoma tumours with increased levels of MYCN.

MYCN affects how tumour cells grow and makes them more dependent on a protein called PARP for survival. This means that the tumour cells are specifically killed by a drug that stops PARP working. An advantage to this type of therapy is that normal non-tumour cells are not harmed so the damaging side-effects often seen with chemotherapy are reduced.

The study, funded by childhood cancer research charity Children with Cancer UK, was led by Dr Helen Bryant and Dr David King in Sheffield, in collaboration with Professor Louis Chesler at The Institute of Cancer Research (ICR).

They found that the use of PARP inhibitors alone, and alongside chemotherapy, was effective in killing neuroblastoma cells, leaving behind healthy cells. This is one of the first studies to show this in neuroblastoma cells and in tumour models.

Dr David King, childrens doctor at Sheffield Children's NHS Foundation Trust and Children with Cancer UK researcher, said:

Children with neuroblastoma and MYCN currently receive some of the most intense treatment used for any type of cancer. The harsh treatment causes numerous side effects and children often have long hospital stays. And despite the treatment, only about half of children with high-risk neuroblastoma will survive. PARP inhibitors are known to have very few side effects in adults and we have shown they may be an effective treatment for neuroblastoma. Their use in neuroblastoma could mean more children survive the disease and need less toxic treatment.

We have shown that PARP inhibitors kill neuroblastoma cells with MYCN in the laboratory. The next step is to see whether they are beneficial in children with neuroblastoma, probably in combination with chemotherapy or radiotherapy. This would be done in a clinical trial.

The ICR is an internationally leading research centre in the study of childhood cancers and cancers in children, teenagers and young adults.

Find out more

Dr Helen Bryant, research group lead and senior lecturer at Sheffield University, said:

Our study has examined the way DNA is damaged and repaired one of the features common in all cancers is that there are changes in that process. We were interested in how that process changes in neuroblastoma and whether we can exploit those changes to specifically kill cancer cells and leave the normal cells around the tumour unharmed. In this way we hope to develop kinder and less toxic therapies for children.

PARP inhibitors are being used successfully in women with breast and ovarian cancer so we are optimistic that this can be translated fairly quickly into children with neuroblastoma.

Mark Brider, Chief Executive Officer, Children with Cancer UK, said:

Neuroblastoma is one of the most common childhood tumours with around 100 children, mostly under five years old, diagnosed every year in the UK. Yet it also has one of the lowest survival rates in its high-risk form the survival rate is sadly around just 50%. It remains one of the most difficult childhood cancers to cure.

It is crucial that we find more effective and personalised treatments for children with neuroblastoma. The findings of Dr Bryant, Dr King and the teams in Sheffield and London represent an important step towards the development of new and kinder treatments that reduce the burden of toxicity for young cancer patients and improve survival rates in this aggressive and hard-to-treat cancer.

We are building a new state-of-the-art drug discovery centre to create more and better drugs for cancer patients. The centre is a 75m project and we now have less than 2m to raise. Help us finish and equip the building to get our research off to the best possible start.

Find out more

Alice Latham, 3, from Derbyshire, was diagnosed with high-risk neuroblastoma, with the MYCN gene, a week before her second birthday in January 2019. Her parents, Jamie and Helena, explain the harmful side-effects of Alices treatment.

Alices neuroblastoma treatment has been very aggressive and harsh on her body, she has experienced many side effects, including hair and weight loss. The treatment may also have an impact on her later in life she may not grow to her full height and there is a chance she may not be able to carry children. If treatments could be developed that are less harmful to childrens growing bodies that would be incredible, said Helena.

Jamie added:

As a parent you know nothing about neuroblastoma you understand when you get the diagnosis that the prognosis for the high-risk form is 40-50% survival after all of the treatment. The research for this type of cancer has really lagged behind and the treatment is very hard hitting. It is vital for charities like Children with Cancer UK step in and continue to fund this lifesaving research.

View post:
Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma - The Institute of Cancer Research

Recommendation and review posted by Bethany Smith

CNET's new video series looks at how to survive the end of the world.

Can a missile bunker protect you from a nuclear blast? Can an escape pod save you from a megatsunami? Could we put our bodies into cryosleep to avoid the apocalypse altogether?

On July 6, CNET is bringing you Hacking the Apocalypse, a new series looking at high-tech solutions to the escape the end of the world. The six-part series launches on YouTube and CNET on Monday, July 6, with a new episode every day.

Subscribe to the CNET Now newsletter for our editors' picks for the most important stories of the day.

In each episode, I take you to meet everyone from preppers to pandemic experts, and I'll road test some fascinating tech that could save the world. Plus, you can check out the accompanying stories, covering what you need to know about the end of the world.

We crossed the United States over the course of three months to meet the bright minds trying to hack a way out of the apocalypse and then crammed everything into a six-episode survival guide:

Hacking the Apocalypse host Claire Reilly at the Mutter Museum in Philadelphia.

When we first started filming Hacking the Apocalypse, long before the coronavirus pandemic, I asked one of the world's top health experts whether a "mutant bat influenza" could catch us off-guard. Little did we know how prophetic that moment would be. The experts warned us, and they were right. In 2020, we've faced a once-in-a-century pandemic and seen what happens when a global health emergency plays out in real time.

For our first episode in this series, we visit the Mutter Museum in Philadelphia to learn about the last major pandemic we faced (it wasn't pretty) and speak to the leading public health experts at the Johns Hopkins Center for Health Security about how we battle a pandemic in the 21st century.

But the big innovation? We speak to scientists in Tennessee who are researching human immunity to help us fight the coronavirus, and to a team of researchers finding life-saving drugs using the world's most powerful supercomputer.

Watch Hacking the Apocalypse: Pandemic on July 6.

How long would we survive if the whole planet went into a full-scale nuclear winter? We travel to Boulder, Colorado, to learn the science behind nuclear winter with an atmospheric scientist and nuclear expert, Professor Brian Toon.

Then we head into the heartland of Kansas (we can't tell you where) to visit a real-life nuclear bunker, made for the world's richest preppers. Turns out avoiding nuclear winter doesn't mean sacrificing luxury.

Watch Hacking the Apocalypse: Nuclear Winter on July 6.

Droughts in California, catastrophic fires in Australia -- the impacts of climate change are only going to get worse. In this episode, we learn about the real threat of global drought, before visiting a lab in New York to learn how scientists could turn toxic waste into drinking water.

Then it's off to New Jersey to visit Bowery Farming, a company that's created a space-aged vertical farm, inside a warehouse, to grow food with 90% less water.

Watch Hacking the Apocalypse: Global Drought on July 7.

This orange ball could be the only thing standing between me and certain disaster.

The coast off the Pacific Northwest is a hotzone for catastrophic earthquakes, so what better place to test out a tsunami survival pod? In this episode, we speak to one of the world's leading seismological experts to find out just what happens when the Earth shakes, before heading to Seattle to road test (or should that be water test?) a tiny escape pod that could save us from tsunami devastation.

Watch Hacking the Apocalypse: Tsunami on July 8.

If the end of the world is coming, could we cheat death by putting our bodies into stasis? To answer that question, we visit the facilities of the Alcor Life Extension Foundation, a company promising a second life in the future through the power of cryonics. Delving into the murky world of cryonics is fascinating (and a little haunting). While the hope of escaping death might sound promising, the scientific proof leaves a lot to be desired.

Watch Hacking the Apocalypse: Cryonics on July 9.

If the s--- really hits the fan, could we just bypass the apocalypse and escape the planet altogether? In our final episode of Hacking the Apocalypse, we visit NASA and learn about the space agency's bid to get humans back on the moon and on to Mars. And to get a sense of what life will look like once we've become a multi-planetary species, we talk to the team behind Marsha, a 3D-printed Mars habitat that could be our new home on the red planet.

Watch Hacking the Apocalypse: Escape the Planet on July 10.

Now playing: Watch this: Hacking the Apocalypse trailer

1:00

Link:
Hacking the Apocalypse: Your new guide to surviving the end of the world - CNET

Recommendation and review posted by Bethany Smith

Zolt speech

Whilst the media reports on generational tremors taking place on the streets and campuses of the United States of America, and institutions stroke their metaphorical chins contemplating ways to change, a much more radical shift is taking place that seems to be going unnoticed.

Mainstream media are missing the story about how people are taking back control of their physical bodies and dedicating their efforts to the enhancement of their own lives. For years now, biohacking has been on the rise: nootropics, supplements, technological implants being just some of the favoured tools to take apart ones body and rebuild it in a better way. Not only that, there is a genuine interest in better understanding our genetic make up and using that to optimise our personal performance. You can see this in the rapid rise of commercial genetic testing services that are now affordable for everyone today.

Even more radical than that is the Transhumanist Movement. A movement that believes in using science and technology to overcome death and fundamentally change the very nature of the human being itself. Its a movement made up of various factions and slightly different beliefs but there is one man who could be said to be have become its natural leader. And that is Zoltan Istvan.

Zoltan has a more radical idea of change than almost anything else you are seeing on your TV screens today but the mainstream media continue to miss him. Thats why its good to see he has made his own documentary film explaining to a broader audience what hes doing, how it all works, and why they should be interested in transhumanism at all.

Immortality or Bust, winner of the BreakoutAwardat the Raw Science Film Festival in Los Angeles, follows Zoltan on his2 year campaign running for President of the US. The film starts by explaining his passion for this transhumanist cause and shows him building a custom-made Bluebird motorhome like his father drove when he was a kid, turning it into a mobile coffin to take him on his journey to Washington DC. There he is to deliver his Transhumanist Bill of Rights.

He enlists friends and family in his quest but we also see him travelling to meet unbelievers and skeptics too, putting his case for Transhumanism over traditional religion. At one point in the documentary he reminds us that atheists never bomb anyone. An important plank of his policy platform is to drastically reduce military funding and redistribute that investment into science. He makes a strong argument that we are living in a military-industrial complex that is out of date, whilst the war we should really be fighting, in this century, is the war on cancer.

Hes actually fighting a war on ageing. For at the heart of transhumainsm is the idea of life extension. As the title suggests, it is life extension that ties together the threads of the film. Those threads include a man on a mission to spread the word of Transhumanism, a U.S. Presidential candidate coming face to face with the religiosity of his nation, and a son whose father has had four heart attacks and whom he would love to protect so he can live forever. These three stories together depict Zoltan as the impossibly human face of Transhumanism.

Over 731 days we follow him as he presents his ideas virtually in Second Life, meets with the Terasem Movement where people download their thoughts and upload their mind files, debates with a crowd of Evangelical Christians and introduces us to the Immortalists at The Church of Perpetual Life . The culmination is when he tries to pin his Transhumanist Bill of Rights on the US Capitol building in Washington DC. After reading out the Bill, he attempts to attach the piece of paper to a wall and is prevented from doing so by a policemen who redirects him to Senator Barbara Boxers office. It is there where the paper is politely filed by an administrative assistant who promises to pass it on at the very first opportunity. A scene that demonstrates just how impenetrable the system is to radical ideas, or any idea of change at all.

zolt with bus in DC

I caught up with Zoltan on the eve of the films launch and asked him whether he will ever run again. We are going to come to a point, probably twelve years from now when the things Ive been talking about really make sense. Technology will catch up and these things will become the norm. Hopefully then a lot of my policies will start to be revisited, and people will say, wait a sec, hes been talking about these things from the very beginning.

My ideas are still pretty far out there, and therere no significant comparison to them in a political sense yet. I think it will take some revolutionary technology like brain implants or an ageing reversal gene shot that makes my ideas go mainstream.

Sometimes I feel I belong to the Star Trek era and not the early 21st Century Earth. But that could change quickly if the technology changes humanity enough, and then the politics I represent are needed in a hurry.

Its an insightful point because whilst most media headlines and future of work reports occupy themselves with tales of automated futures that displace human beings from the jobs they need or love, Zoltans vision is to harness automation in the service of an enhanced human being.

The film is a tale of presidential pilgrimage but also a love letter to longevity when facing the pain that death bestows on us all. But for the most part it is two fingers up to determinism, spitting in the eye of appeasement and challenging us all to make a radical change not leave it to someone else. I hope that a younger generation will watch it. They may not be interested in life extension or yet face dilemmas of mortality but this film would provide them with a welcome antidote to the relentless victimhood in todays culture and its obsessive search for the security of safe spaces. Zoltan takes on life and bends it to his will. I hope an emerging generation will absorb that message and rekindle their autonomy, and in Zoltans own words, have no respect for fate.

Immortality or Bust trailer here. Film now available on Amazon, iTunes, Vimeo

Read more:
Immortality Or Bust: Transhumanism In The White House - Forbes

Recommendation and review posted by Bethany Smith

It is not a secret that the F-35A, the CTOL (Convetional Take Off and Landing) variant of the Lightning II aircraft, will be dual capable aircraft (DCA), meaning that it will have the ability to deliver nuclear ordnance as well as conventional weapons. Such dual capability is expected to be included in the Block 4 software release, with initial capability for the B61-12 weapon.

Although the F-35A DCA is scheduled to achieve nuclear certification in January, 2023, testing at the 461st FLTS, the test squadron that oversees developmental testing of all variants of the fifth-generation F-35 Lightning II at Edwards Air Force Base, California, has started in 2019.

Images just released by the F-35 Joint Program Office (the Department of Defense's agency responsible for developing and acquiring the F-35A/B/C) show various drop tests of inert nuclear bombs between 2019 and 2020.

The photos distributed to the DVIDS distribution service provide additional details about the dates when the tests were carried out: the first separation test with AF-1 flown by Jason Shulze was conducted on June 27, 2019; sixth separation test with AF-1 (pilot unspecified) was carried out on November 7, 2019; first separation test from AF-6 flown by Maj. Chris "Beast" Taylor was conducted on November 25, 2019.

Separation test #6 with AF-1 was carried out with F-35 AF-01 flown by Maj. Rachael "Banshee" Winiecki on February 6, 2020. A more recent test with AF-6 was carried out on April 2, 2020. (No additional detail can be gathered about this test.)

An F-35A releases ordnance during a dual capable aircraft (DCA) test flight over Edwards Air Force Base, California, June 27, 2019. F-35 Joint Program Office

An F-35A releases ordnance during a dual capable aircraft (DCA) test flight over Edwards Air Force Base, California, October 22, 2019. F-35 Joint Program Office

An F-35A releases ordnance during a dual capable aircraft (DCA) test flight over Edwards Air Force Base, California, February 6, 2020. F-35 Joint Program Office

An F-35A releases ordnance during a dual capable aircraft (DCA) test flight over Edwards Air Force Base, California, April 2, 2020. F-35 Joint Program Office

As already explained in a previous article:

"The B61-12 represent the latest LEP (Life-Extention Program) upgrade to the B61 line of nuclear weapons that has already been extensively tested with the F-15E Strike Eagles of the 422nd Test and Evaluation Squadron, back in 2015."

"The Life Extension Program or LEP, will replace the B61 -3, -4, -7, and -10 mods, with the -12 that, along with the B83, will become the only remaining gravity delivered nukes in the inventory."

"'The B61-12 gravity bomb ensures the current capability for the air-delivered leg of the US strategic nuclear triad well into the future for both bombers and dual-capable aircraft supporting NATO,' said Paul Waugh, AFNWC's Air-Delivered Capabilities director in a US Air Force release dated Apr. 13 (more or less when the world learned about the first use of the famous MOAB in Afghanistan). The B61-12 will be compatible with the B-2A, B-21, F-15E, F-16C/D, F-16 MLU, F-35 and PA-200 aircraft.

"The LEP increases the B61's accuracy so much that it will have the same capability against hardened targets as the much more powerful weapons it is replacing."

An F-35A releases ordnance during a dual capable aircraft (DCA) test flight over Edwards Air Force Base, California, November 7, 2019. F-35 Joint Program Office

With the integration of the B61-12, the "iconic nuclear fighter role, performed in the past by the F-15E and F-16, is being passed to the F-35A to play a future role in national security." Other partner nations are slated to transfer the NATO nuclear role to the F-35A in the future.

Read more here:
Here are the first photos of the F-35A dropping inert nuclear bombs during testing - Business Insider - Business Insider

Recommendation and review posted by Bethany Smith

LOS ANGELES, United States:

Quality Market Research on Global Magnolia Officinalis Bark Extract Market with Decision Making Insights, Industry Assessment, Trends, Competitive Landscape, Investment & Business Strategies and Forecast by 2026.

The global Magnolia Officinalis Bark Extract market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Magnolia Officinalis Bark Extract market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Magnolia Officinalis Bark Extract market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market.

Get the Sample of this Report with Detail TOC and List of [emailprotected]https://www.qyresearch.com/sample-form/form/1887383/global-magnolia-officinalis-bark-extract-industry-research-report-growth-trends-and-competitive-analysis-2020-2026

The research report covers the trends that are currently implemented by the major manufacturers in the Magnolia Officinalis Bark Extract market including adoption of new technology, government investments on R&D, shifting in perspective towards sustainability, and others. Additionally, the researchers have also provided the figures necessary to understand the manufacturer and its contribution to both regional and global market:

Key Players:

Lvyin Biotech, Shenyang Phytocare Ingredients, Cosphatec, Hunan Health-Guard Bio-Tech, Samsara herbs, Solaray, Active Herb, LiftMode, Life Extension, Hawaii Pharm LLC, Piping Rock Health Products

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Magnolia Officinalis Bark Extract Market which would mention How the Covid-19 is Affecting the Magnolia Officinalis Bark Extract Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Magnolia Officinalis Bark Extract Players to Combat Covid-19 Impact.

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Magnolia Officinalis Bark Extract market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Market Segments Covered:

Global Magnolia Officinalis Bark Extract Market Segmentation by Product:Magnolia Bark OilPowder

Global Magnolia Officinalis Bark Extract Market Segmentation by Application:MedicinesHealth FoodsCosmetic and Daily ChemicalsFoodOther

Regions Covered in the Global Magnolia Officinalis Bark Extract Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report answers important questions that companies may have when operating in the global Magnolia Officinalis Bark Extract market. Some of the questions are given below:

What will be the size of the global Magnolia Officinalis Bark Extract market in 2025? What is the current CAGR of the global Magnolia Officinalis Bark Extract market? Which product is expected to show the highest market growth? Which application is projected to gain a lions share of the global Magnolia Officinalis Bark Extract market? Which region is foretold to create the most number of opportunities in the global Magnolia Officinalis Bark Extract market? Will there be any changes in market competition during the forecast period? Which are the top players currently operating in the global Magnolia Officinalis Bark Extract market? How will the market situation change in the coming years? What are the common business tactics adopted by players? What is the growth outlook of the global Magnolia Officinalis Bark Extract market?

The scope of the Report:

The report segments the global Magnolia Officinalis Bark Extract market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Magnolia Officinalis Bark Extract market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Customized Report as per Your [emailprotected]https://www.qyresearch.com/customize-request/form/1887383/global-magnolia-officinalis-bark-extract-industry-research-report-growth-trends-and-competitive-analysis-2020-2026

Strategic Points Covered in TOC:

1 Report Overview1.1 Research Scope1.2 Top Magnolia Officinalis Bark Extract Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type1.3.1 Global Magnolia Officinalis Bark Extract Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)1.3.2 Magnolia Bark Oil1.3.3 Powder1.4 Market Segment by Application1.4.1 Global Magnolia Officinalis Bark Extract Consumption by Application: 2015 VS 2020 VS 20261.4.2 Medicines1.4.3 Health Foods1.4.4 Cosmetic and Daily Chemicals1.4.5 Food1.4.6 Other1.5 Study Objectives1.6 Years Considered

2 Global Market Perspective2.1 Global Magnolia Officinalis Bark Extract Revenue (2015-2026)2.1.1 Global Magnolia Officinalis Bark Extract Revenue (2015-2026)2.1.2 Global Magnolia Officinalis Bark Extract Sales (2015-2026)2.2 Global Magnolia Officinalis Bark Extract Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 20262.2.1 Global Magnolia Officinalis Bark Extract Sales by Regions (2015-2020)2.2.2 Global Magnolia Officinalis Bark Extract Revenue by Regions (2015-2020)2.3 Global Top Magnolia Officinalis Bark Extract Regions (Countries) Ranking by Market Size2.4 Magnolia Officinalis Bark Extract Industry Trends2.4.1 Magnolia Officinalis Bark Extract Market Trends2.4.2 Magnolia Officinalis Bark Extract Market Drivers2.4.3 Magnolia Officinalis Bark Extract Market Challenges2.4.4 Magnolia Officinalis Bark Extract Market Restraints2.4.5 Primary Interviews with Key Magnolia Officinalis Bark Extract Players: Views for Future

3 Competitive Landscape by Manufacturers3.1 Global Top Magnolia Officinalis Bark Extract Manufacturers by Sales (2015-2020)3.1.1 Global Magnolia Officinalis Bark Extract Sales by Manufacturers (2015-2020)3.1.2 Global Magnolia Officinalis Bark Extract Sales Market Share by Manufacturers (2015-2020)3.1.3 Global 5 and 10 Largest Manufacturers by Magnolia Officinalis Bark Extract Sales in 20193.2 Global Top Manufacturers Magnolia Officinalis Bark Extract by Revenue3.2.1 Global Magnolia Officinalis Bark Extract Revenue by Manufacturers (2015-2020)3.2.2 Global Magnolia Officinalis Bark Extract Revenue Share by Manufacturers (2015-2020)3.2.3 Global Magnolia Officinalis Bark Extract Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Magnolia Officinalis Bark Extract as of 2019)3.4 Global Magnolia Officinalis Bark Extract Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers Magnolia Officinalis Bark Extract Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into Magnolia Officinalis Bark Extract Market3.7 Key Manufacturers Magnolia Officinalis Bark Extract Product Offered3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type4.1 Global Magnolia Officinalis Bark Extract Historic Market Review by Type (2015-2020)4.1.2 Global Magnolia Officinalis Bark Extract Sales Market Share by Type (2015-2020)4.1.3 Global Magnolia Officinalis Bark Extract Revenue Market Share by Type (2015-2020)4.1.4 Magnolia Officinalis Bark Extract Price by Type (2015-2020)4.1 Global Magnolia Officinalis Bark Extract Market Estimates and Forecasts by Type (2021-2026)4.2.2 Global Magnolia Officinalis Bark Extract Sales Forecast by Type (2021-2026)4.2.3 Global Magnolia Officinalis Bark Extract Revenue Forecast by Type (2021-2026)4.2.4 Magnolia Officinalis Bark Extract Price Forecast by Type (2021-2026)

5 Global Magnolia Officinalis Bark Extract Market Size by Application5.1 Global Magnolia Officinalis Bark Extract Historic Market Review by Application (2015-2020)5.1.2 Global Magnolia Officinalis Bark Extract Sales Market Share by Application (2015-2020)5.1.3 Global Magnolia Officinalis Bark Extract Revenue Market Share by Application (2015-2020)5.1.4 Magnolia Officinalis Bark Extract Price by Application (2015-2020)5.2 Global Magnolia Officinalis Bark Extract Market Estimates and Forecasts by Application (2021-2026)5.2.2 Global Magnolia Officinalis Bark Extract Sales Forecast by Application (2021-2026)5.2.3 Global Magnolia Officinalis Bark Extract Revenue Forecast by Application (2021-2026)5.2.4 Magnolia Officinalis Bark Extract Price Forecast by Application (2021-2026)

6 North America6.1 North America Magnolia Officinalis Bark Extract Breakdown Data by Company6.2 North America Magnolia Officinalis Bark Extract Breakdown Data by Type6.3 North America Magnolia Officinalis Bark Extract Breakdown Data by Application6.4 North America Magnolia Officinalis Bark Extract Breakdown Data by Countries6.4.1 North America Magnolia Officinalis Bark Extract Sales by Countries6.4.2 North America Magnolia Officinalis Bark Extract Revenue by Countries6.4.3 U.S.6.4.4 Canada

7 Europe7.1 Europe Magnolia Officinalis Bark Extract Breakdown Data by Company7.2 Europe Magnolia Officinalis Bark Extract Breakdown Data by Type7.3 Europe Magnolia Officinalis Bark Extract Breakdown Data by Application7.4 Europe Magnolia Officinalis Bark Extract Breakdown Data by Countries7.4.1 Europe Magnolia Officinalis Bark Extract Sales by Countries7.4.2 Europe Magnolia Officinalis Bark Extract Revenue by Countries7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia

8 Asia Pacific8.1 Asia Pacific Magnolia Officinalis Bark Extract Breakdown Data by Company8.2 Asia Pacific Magnolia Officinalis Bark Extract Breakdown Data by Type8.3 Asia Pacific Magnolia Officinalis Bark Extract Breakdown Data by Application8.4 Asia Pacific Magnolia Officinalis Bark Extract Breakdown Data by Regions8.4.1 Asia Pacific Magnolia Officinalis Bark Extract Sales by Regions8.4.2 Asia Pacific Magnolia Officinalis Bark Extract Revenue by Regions8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 India8.4.7 Australia8.4.8 Taiwan8.4.9 Indonesia8.4.10 Thailand8.4.11 Malaysia8.4.12 Philippines8.4.13 Vietnam

9 Latin America9.1 Latin America Magnolia Officinalis Bark Extract Breakdown Data by Company9.2 Latin America Magnolia Officinalis Bark Extract Breakdown Data by Type9.3 Latin America Magnolia Officinalis Bark Extract Breakdown Data by Application9.4 Latin America Magnolia Officinalis Bark Extract Breakdown Data by Countries9.4.1 Latin America Magnolia Officinalis Bark Extract Sales by Countries9.4.2 Latin America Magnolia Officinalis Bark Extract Revenue by Countries9.4.3 Mexico9.4.4 Brazil9.4.5 Argentina

10 Middle East and Africa10.1 Middle East and Africa Magnolia Officinalis Bark Extract Breakdown Data by Type10.2 Middle East and Africa Magnolia Officinalis Bark Extract Breakdown Data by Application10.3 Middle East and Africa Magnolia Officinalis Bark Extract Breakdown Data by Countries10.3.1 Middle East and Africa Magnolia Officinalis Bark Extract Sales by Countries10.3.2 Middle East and Africa Magnolia Officinalis Bark Extract Revenue by Countries10.3.3 Turkey10.3.4 Saudi Arabia10.3.5 U.A.E

11 Company Profiles11.1 Lvyin Biotech11.1.1 Lvyin Biotech Corporation Information11.1.2 Lvyin Biotech Business Overview11.1.3 Lvyin Biotech Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.1.4 Lvyin Biotech Magnolia Officinalis Bark Extract Products and Services11.1.5 Lvyin Biotech SWOT Analysis11.1.6 Lvyin Biotech Recent Developments11.2 Shenyang Phytocare Ingredients11.2.1 Shenyang Phytocare Ingredients Corporation Information11.2.2 Shenyang Phytocare Ingredients Business Overview11.2.3 Shenyang Phytocare Ingredients Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.2.4 Shenyang Phytocare Ingredients Magnolia Officinalis Bark Extract Products and Services11.2.5 Shenyang Phytocare Ingredients SWOT Analysis11.2.6 Shenyang Phytocare Ingredients Recent Developments11.3 Cosphatec11.3.1 Cosphatec Corporation Information11.3.2 Cosphatec Business Overview11.3.3 Cosphatec Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.3.4 Cosphatec Magnolia Officinalis Bark Extract Products and Services11.3.5 Cosphatec SWOT Analysis11.3.6 Cosphatec Recent Developments11.4 Hunan Health-Guard Bio-Tech11.4.1 Hunan Health-Guard Bio-Tech Corporation Information11.4.2 Hunan Health-Guard Bio-Tech Business Overview11.4.3 Hunan Health-Guard Bio-Tech Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.4.4 Hunan Health-Guard Bio-Tech Magnolia Officinalis Bark Extract Products and Services11.4.5 Hunan Health-Guard Bio-Tech SWOT Analysis11.4.6 Hunan Health-Guard Bio-Tech Recent Developments11.5 Samsara herbs11.5.1 Samsara herbs Corporation Information11.5.2 Samsara herbs Business Overview11.5.3 Samsara herbs Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.5.4 Samsara herbs Magnolia Officinalis Bark Extract Products and Services11.5.5 Samsara herbs SWOT Analysis11.5.6 Samsara herbs Recent Developments11.6 Solaray11.6.1 Solaray Corporation Information11.6.2 Solaray Business Overview11.6.3 Solaray Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.6.4 Solaray Magnolia Officinalis Bark Extract Products and Services11.6.5 Solaray SWOT Analysis11.6.6 Solaray Recent Developments11.7 Active Herb11.7.1 Active Herb Corporation Information11.7.2 Active Herb Business Overview11.7.3 Active Herb Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.7.4 Active Herb Magnolia Officinalis Bark Extract Products and Services11.7.5 Active Herb SWOT Analysis11.7.6 Active Herb Recent Developments11.8 LiftMode11.8.1 LiftMode Corporation Information11.8.2 LiftMode Business Overview11.8.3 LiftMode Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.8.4 LiftMode Magnolia Officinalis Bark Extract Products and Services11.8.5 LiftMode SWOT Analysis11.8.6 LiftMode Recent Developments11.9 Life Extension11.9.1 Life Extension Corporation Information11.9.2 Life Extension Business Overview11.9.3 Life Extension Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.9.4 Life Extension Magnolia Officinalis Bark Extract Products and Services11.9.5 Life Extension SWOT Analysis11.9.6 Life Extension Recent Developments11.10 Hawaii Pharm LLC11.10.1 Hawaii Pharm LLC Corporation Information11.10.2 Hawaii Pharm LLC Business Overview11.10.3 Hawaii Pharm LLC Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.10.4 Hawaii Pharm LLC Magnolia Officinalis Bark Extract Products and Services11.10.5 Hawaii Pharm LLC SWOT Analysis11.10.6 Hawaii Pharm LLC Recent Developments11.11 Piping Rock Health Products11.11.1 Piping Rock Health Products Corporation Information11.11.2 Piping Rock Health Products Business Overview11.11.3 Piping Rock Health Products Magnolia Officinalis Bark Extract Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.11.4 Piping Rock Health Products Magnolia Officinalis Bark Extract Products and Services11.11.5 Piping Rock Health Products SWOT Analysis11.11.6 Piping Rock Health Products Recent Developments

12 Value Chain and Sales Channels Analysis12.1 Magnolia Officinalis Bark Extract Value Chain Analysis12.2 Sales Channels Analysis12.2.1 Magnolia Officinalis Bark Extract Sales Channels12.2.2 Magnolia Officinalis Bark Extract Distributors12.3 Magnolia Officinalis Bark Extract Customers

13 Estimates and Projections by Regions (2021-2026)13.1 Global Magnolia Officinalis Bark Extract Sales Forecast (2021-2026)13.1.1 Global Magnolia Officinalis Bark Extract Sales Forecast by Regions (2021-2026)13.1.2 Global Magnolia Officinalis Bark Extract Revenue Forecast by Regions (2021-2026)13.2 North America Market Size Forecast (2021-2026)13.2.1 North America Magnolia Officinalis Bark Extract Sales Forecast (2021-2026)13.2.2 North America Magnolia Officinalis Bark Extract Revenue Forecast (2021-2026)13.2.3 North America Magnolia Officinalis Bark Extract Size Forecast by County (2021-2026)13.3 Europe Market Size Forecast (2021-2026)13.3.1 Europe Magnolia Officinalis Bark Extract Sales Forecast (2021-2026)13.3.2 Europe Magnolia Officinalis Bark Extract Revenue Forecast (2021-2026)13.3.3 Europe Magnolia Officinalis Bark Extract Size Forecast by County (2021-2026)13.4 Asia Pacific Market Size Forecast (2021-2026)13.4.1 Asia Pacific Magnolia Officinalis Bark Extract Sales Forecast (2021-2026)13.4.2 Asia Pacific Magnolia Officinalis Bark Extract Revenue Forecast (2021-2026)13.4.3 Asia Pacific Magnolia Officinalis Bark Extract Size Forecast by Region (2021-2026)13.5 Latin America Market Size Forecast (2021-2026)13.5.1 Latin America Magnolia Officinalis Bark Extract Sales Forecast (2021-2026)13.5.2 Latin America Magnolia Officinalis Bark Extract Revenue Forecast (2021-2026)13.5.3 Latin America Magnolia Officinalis Bark Extract Size Forecast by County (2021-2026)13.6 Middle East and Africa Market Forecast13.6.1 Middle East and Africa Magnolia Officinalis Bark Extract Sales Forecast (2021-2026)13.6.2 Middle East and Africa Magnolia Officinalis Bark Extract Revenue Forecast (2021-2026)13.6.3 Middle East and Africa Magnolia Officinalis Bark Extract Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Contact US:QY Research, INC.17890 Castleton, Suite 218,Los Angeles, CA 91748USA: +1 626 428 8800India: +91 9766 478 224Email [emailprotected]Web http://www.qyresearch.com

Here is the original post:
Magnolia Officinalis Bark Extract Market 2020| Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments...

Recommendation and review posted by Bethany Smith

Editors note: Exposure to UV-C light poses known threats to human health. While the research discussed in this story examined ways that UV-C might be broadly deployed to stem the spread of COVID-19, it is presented only as information about new research. Readers are strongly cautionednot to experiment on their own with UV-C as an antimicrobial measure.

COVID-19 has upended society and brought chaos to generous swaths of the global economy, as governments have locked down to prevent the spread of the virus. The pandemic has also boosted interest in a variety of technologies that might help in the coronavirus fightincluding the use of ultraviolet light to sterilize scarce personal protective equipment (PPE) such as face masks, for reuse.

In recent papers, two research teams have now proposed approaches to take the use of UV-C much farther. The two groups lay out different schemes for using this high-energy light to scrub the pandemic virus from the air in occupied indoor spaceswhile still keeping the occupants safe from the usual harmful long-term effects of exposure to UV radiation. The teams argue that the approaches they suggest, if widely adopted, could sharply reduce viral transmission in public indoor spaces, and thereby help the world resume something closer to normal economic activity.

The antimicrobial effects of UV-C lightwhich occupies the wavelength band from 200 to 280 nmhave long been known, and 254-nm mercury-vapor germicidal lamps are routinely used to disinfect empty hospital rooms, clean up tainted water, and otherwise cleanse surfaces and areas where bacteria and viruses may lurk. The problem is that the same light that hammers pathogenic airborne bacteria also wreaks havoc on human cells, with long-term impacts such as skin cancer and eye damage.

As a result, much of the recent interest in leveraging UV-C light against the COVID-19 virus, SARS-CoV-2, has centered around possible uses in disinfecting PPE for doctors, nurses and first responders. (One such effort, focusing on a low-cost system that can be used to disinfect scarce N95 face masks for reuse in resource-limited areas, is being pursued by an interdisciplinary team including OSA Fellow and past president Thomas Baer.)

The teams behind the two recent papers favor substantially broadening the use of UV-C against SARS-CoV-2. They suggest that, with the right precautions and setups, the light might be used as a prophylactic in occupied indoor spaces such as workplaces, schools, hospitals and other public areas, silently scrubbing the air of the coronavirus even as the occupants of the buildings go about their daily lives.

One of the studies was led by OSA Fellow Javier Garca de Abajo of the Institute of Photonic SciencesICFO, Spain, and tapped a multinational, interdisciplinary team of researchers in virology, aerosols, immunology and other areas (ACS Nano, doi: 10.1021/acsnano.0c04596). In the study, the researchers looked at how the judicious, strategic installation of UV-C sources might attack the most common routes of indoor viral transmission.

The team began by inventorying the indoor places and systems most likely to spread the virus. These, the researchers argue, include interior ventilation systems in a wide range of settings, which can spread airborne viruses; infrastructure items touched by many persons, such as elevator buttons, stair rails and public-transit handles; and common public facilities with repeated, periodic high use, such as public toilets, storerooms and other areas.

The ICFO-led team argues that antimicrobial UV-C light sources could be placed in a variety of locations associated with viral spread, such as ventilation systems and other areas. The lamps could then be operated without a direct optical pathto humans, or while the roomsare not in use, to help reduce virus propagation without endangering human health. [Image: Sketches by Nacho Gaubert] [Enlarge image]

The team then analyzed how a range of UV-C sources, including LEDs and conventional mercury-vapor lamps, could be safely deployed to attack coronavirus in these individual spread scenarios. For example, the team argues that lamps could be deployed inside ventilation systems, with no direct optical path to occupants in the building, and run continuously, to disinfect ambient air. In other settings such as public restrooms, high-intensity UV-C light could be applied during the periods in which the rooms are unoccupied. And frequently touched surfaces, such as elevator buttons, might be subjected to continuous, weak UV-C illumination for ongoing disinfectionas human interactions with these surfaces tend to be brief, and thus would involve only a very low dose of radiation.

The team acknowledges that putting such an approach into effect would require a massive new deployment of UV lighting, with a correspondingly huge required uptick in its production. Yet the cost, they argue, may not be excessive, given the scale of the problem humanity now confrontsnot just in human mortality, but in the economic devastation that antiviral lockdowns have created.

The team estimates, in fact, that disinfection with fluorescence lamps could be implemented at a cost of a few dollars per person with minimum changes in infrastructure. Thus, they argue, a global capital investment of a few billion [U.S.] dollars could protect on the order of 109 indoor workers worldwide. The authors add, however, that current manufacturers of UV-C sources may have difficulty coping with the expected rise in demand originated by the SARS-CoV-2, pandemic, as the global market for UV-C light barely reaches one billion dollars a year at present.

Another team, based at Columbia Universitys Irving Medical Center, USA, took a different view of how UV-C might be used to fight coronavirus in occupied indoor settings (Sci. Reports, doi: 10.1038/s41598-020-67211-2). The team focused in particular on the specific wavelengths of UV-C light that might be used against the virusstressing that not all UV-C light is necessarily the same in terms of its hazard to human health.

Conventional germicidal lamps operate at a wavelength of 254 nm, as that is one of the sweet spots for UV-C absorption by DNA or RNA molecules; the light thus scrambles and inactivates the pathogens genetic machinery. It can also penetrate into the skin and eyes, causing similar genetic and other damage to living human cells.

The Columbia team points out, however, that light in the far UV-C, between 207 and 222 nm, is also effective at killing microorganismsyet studies to date suggest that these wavelengths do not cause the human health issues associated with the 254-nm radiation of germicidal lamps. The reason, according to the team, is that light in the far UV-C penetrates less than a few micrometers into biological materials. Thats too short a distance to pierce the nonliving protective layers of the skin and eye into the living cells beneath. But its more than sufficient to bore into tiny bacteria and viruses.

These considerations, the Columbia team argues, suggest that far-UV-C light should have about the same anti-microbial properties as conventional germicidal UV light, but without producing the corresponding health effects. Thus, they conclude, continuous, low-dose application of light in the wavelength area of 222 nm might be used in occupied public areas to stem the spread of SARS-CoV-2, without posing other hazards to the occupants themselves.

To test the idea out, the team used a misting device to aerosolize two common coronaviruses that were structurally similar to SARS-CoV-2, and then flowed the aerosols through the air in front of a 222-nm UV-C lamp. The researchers found that, at very low doses, the far UV-C light killed more than 99.9% of the viral load. The team is now at work on tests using the actual SARS-CoV-2 pathogenand says that preliminary data suggest that the far-UV-C light effectively kills that virus, too.

Putting these results together with the safety data, the team leader, David J. Brenner, asserted in a press release accompanying the work that far-UV-C at very low doses could be used in combination with other measures, like wearing face masks and washing hands, to limit the transmission of SARS-CoV-2 and other viruses.

View post:
COVID-19: Putting UV-C to Work - Optics & Photonics News

Recommendation and review posted by Bethany Smith

In order to understand how COVID-19 spreads throughout the body, ravaging it in myriad ways, doctors are growing miniature balls or organ-like tissue called organoids, and infecting them again and again.

The results, Nature News reports, are particularly troubling: the miniature lungs, livers, kidneys, hearts, intestines all showed signs of damage. The series of studies reveals with shocking clarity that COVID-19 can cause far more than a lung infection.

Of course, thats not exactly news. This harrowing list of survivors and medical workers horror stories gathered by SFGate includes heart attacks, strokes, long-term lung damage, incontinence, skin damage, and other serious complications for supposed mild cases of the coronavirus:

Thats just one of the many, many stories they gathered about the ways a road to recovery from COVID-19 is neither linear nor something that shouldnt be feared.

That said, for all their benefits, organoids are still imperfect. Per Nature, theyre far more simplistic than a full-sized organ. And because theyre not all connected in the same body, doctors can only use them to study the impacts on a single organ in isolation.

We know the cells die but we dont know how, Weill Cornell Medicine stem cell biologist Shuibing Chen told Nature of her study on miniature lungs.

Even though questions remain, its clear those impacts are serious. Various studies found that the coronavirus caused serious damage in several organs, and may lead to indirect damage in others. It also became clear that the coronavirus can infect and spread through blood vessels, leading to a more serious, widespread case.

To figure that out, biologists will need to develop more sophisticated and realistic organoids and try their experiments again, Nature reports.

It is too early to say how relevant they are, Bart Haagmans, an Erasmus MC virologist who ran a study on gut organoids, told Nature.

Original post:
Mini-Organ Research Reveals What COVID-19 Does to the Body - Futurism

Recommendation and review posted by Bethany Smith

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of theglobal Cryonics Technology market based on various segments. It also provides market size and forecast estimates from year 2019 to 2025 with respect to five major regions, namely;North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America. The Cryonics Technology market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of18 countriesglobally along with current trend and opportunities prevailing in the region.

Cryopreservation technology is used for the preservation of living cells and tissues at very low temperature. Cryonics technology adopted by medical sector to preserve living body organs which can boost the demand of this technology. Government investment in medical sector and increasing deaths caused by incurable diseases are the major driving factor for this industry.

Get a sample copy of this report before purchase at:

https://www.marketinsightsreports.com/reports/07101351264/global-cryonics-technology-market-size-status-and-forecast-2019-2025/inquiry?source=coleofduty&Mode=12

Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics and Other.

This report presents the worldwide Cryonics Technology market size (value, production and consumption), splits the breakdown (data status 2014-2019 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Key Strategic Developments:The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Analytical Tools:The Global Cryonics Technology Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Get full access to this report at:

https://www.marketinsightsreports.com/reports/07101351264/global-cryonics-technology-market-size-status-and-forecast-2019-2025?source=coleofduty&Mode=12

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last five years are identified. The trends and strategies section highlights the likely future developments in the market and suggests approaches.

The research includes historic data from 2014 to 2018 and forecasts until 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Contact US:

Irfan Tamboli (Head of Sales)

Market Insights Reports

Phone: + 1704 266 3234 | Mob: +91-750-707-8687

[emailprotected] | [emailprotected]

See more here:
Cryonics Technology Market Latest Trends and Business Outlook 2020 to 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

By: Lifestyle Desk | New Delhi | Updated: June 27, 2020 12:09:31 pm Heres everything to know about the blood disorder. (Source: Getty Images/Thinkstock)

Sickle cell disease (SCD) is an inherited group of blood disorder which is genetic in nature. It is usually transferred from parents to the child during birth i.e. both the parents can be carries of SCD. Healthy RBCs are round in shape, which moves through small blood vessels and carries oxygen to all parts of the body. In someone who has SCD, the RBC becomes sticky and hard and start to look like C- shaped similar to that of a farm tool sickle. The sickle cells die early, which causes a constant shortage of RBC, which leads to low oxygen carriers in the body, mentioned Dr Rahul Bhargava, director and head, haematology and bone marrow transplant, Fortis Memorial Research Institute, Gurugram. Also, when sickle cells travels they tend to get stuck in small blood vessels and restrict the blood flow. This can cause pain in the joints, chest and other serious problems such as stroke, acute chest syndrome and infections.

Anaemia

SCD can lead to shortage of RBC which makes the patient anaemic. It can lead to less oxygen supply in the body causing fatigue.

Episodes of pain. SCD patients suffer from episodes of periodic pain. Sickle-shaped blood cells can block the flow of blood which in tiny vessels of abdomen, chest and joints, thus leading to pain.

Feet and hands swelling

Sickle-shaped RBC can block then flow of blood which can cause swelling in the hands and feet.

Frequent infections

Sickle cells can damage the spleen and make the person vulnerable to diseases and infections. Vaccination is usually prescribed in childhood to keep infections at bay.

Delayed growth or puberty

RBC is the carrier of oxygen and other nutrients. With low RBC, there is no enough oxygen in the body which can slow the growth in infants and children which leads to delayed puberty in children.

Vision problems

Vision is affected when the flow of blood is affected.

SCD can lead to a lot of complication, including Stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers and more such complications.

SCD can be diagnosed with a simple blood test. Parents are advised to get the screening done before conceiving as it is transmitted from parents. For newborns, the test is done in the hospitals as a routine screening. There is no single treatment for SCD patients and it varies from patient to patient on the basis the symptoms. Before starting any medication, consult a haematologist who specialises in blood disorders.

The only cure for SCD is getting a bone marrow transplant (BMT), which is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Stem cells are easily taken from the donor and planted in the recipient. After the BMT procedure, the patient can lead a healthy and normal life.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

See the rest here:
Sickle Cell Disease: All you need to know - The Indian Express

Recommendation and review posted by Bethany Smith

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

A Blood Cancer Diagnosis

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.

Follow this link:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News

Recommendation and review posted by Bethany Smith

Post COVID-19 Impact on Cancer Stem Cell Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues.

Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following:

Well help you fight this crisis through our business intelligence solutions.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/32

Pre COVID-19 Analysis on Cancer Stem Cell Market

According to a study by the World Health Organization (WHO), cancer is the cause for every one death out of six occurrences. Growing cases of cancers such as breast cancer, lung cancer and others due to poor diet patterns, air pollution, sexually transmitted infections, alcohol consumption. Other types of cancer are liver cancer, pancreas cancer, brain cancer, bladder cancer, colon, and blood cancer. The most common cures for cancer are chemotherapy, radiation, and surgeries. These procedures have an adverse effect on the human body. High doses of radiation and chemotherapy destroy the blood-forming stem cells. Stem cells are the soft tissues of the bone that grow inside the bone marrow. Stem cell transplants restore the blood-forming stem cells. These stem cells grow into platelets, RBCs, and WBCs that are required by the body to fight illness and provide oxygen. Usually, these transplants are done within the family to find the closest match.

Check out How Stem-cell based cancer segment is will generate revenue of $896.9 Mn by the year of 2026. Click here to know more in details @ https://www.researchdive.com/purchase-enquiry/32

According to a study,Cancer Stem Cells Marketby Research Dive, the global market will surpass $1,722.7 million by 2026. Rising number of cancer patients, coupled with the latest advancements in cancer stem cells will upsurge the global market by the year 2026.

Cancer Stem Cells Market Segmentation by Cancer Form

Regional Investment Opportunities:

North America cancer stem cell market is generated revenue of $365.64 million by end of 2018 and is anticipated to rise at 10% CAGR during the analyzed period. Asia-Pacific market registered a growth rate of 11.2% during the forecast period. This market will surpass $367.68 million by 2026, growing from $157.26 million in 2018. China, India, and Japan are the key contributors to the growth of regional market.

Cancer Stem Cells Market Segmentation by Application

Stem Cells for Cancer

Cancer stem cells or CSCs are a subpopulation of cells that has the driving force of carcinogenesis. Characteristics of cancer stem cells are proliferation, and differentiation capabilities and distinctive self-renewal. These characteristics play a vital role in many stages of cancer such as cancer initiation, drug resistance, progression, maintenance, and metastasis or relapse. CSCs have traits that are linked with normal stem cells and are found within hematological cancers or tumors.

Check out How Cancer stem cells market for breast cancer is projected to hold a dominant share, owing to the genetic influences & alcohol use @ https://www.researchdive.com/download-sample/32

Stem Cell-based therapy

According to the World Health Organization (WHO), the most common cause of deaths in women diagnosed with cancer is breast cancer.Global cancer stem cells marketis projected to reach up to $896.9 million by the end of 2026 as the stem cell-based cancer therapy and targeted cancerous stem cell therapy are advancing in the medical field. Cell-based therapy is split into allogenic Stem Cell therapy and autologous Stem Cell therapy. Allogenic Hematopoietic Stem Cell Transplantation is more beneficial than the autologous Hematopoietic Stem Cell Transplantation for Breast cancer based on different aspects such as cancer-free graft & immune-mediated Graft vs Tumor effect mediated by the donors immune cell.

Successful engraftment rates together with lesser transplant-related mortality and the presence of Graft vs Tumor effect made allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity conditioning is the better choice option for the treatment of multiple solid tumors. Due to aforesaid aspects, it is anticipated that allogenic cell therapy will be the rising point for the cancer stem cell market. The global market for stem cell-based cancer therapy is estimated to grow at 9.3% CAGR in 2026 from $440.3 million in 2018.

Advancements in Cancer Stem Cell Transplantation

The prime reason for such huge growth is majorly owed to the rising developments in stem cell therapy of the Asia-Pacific and Europe region. Physicians in Canada are endorsing and promotion of stem cell interventions, which are ethical, legal, and regulatory. U.S. and Canada are leading the cancer stem cell market in the North America region. The North America market is expected to grow over the forecast period and is further projected to generate revenue of $783.8 million by 2026 from its market value of $365.6 million in 2018. While the Asia-Pacific Cancer Stem Cells Market is anticipated to rise to $367.7 Million till 2026 and the Europe Cancer Stem Cells Market is anticipated to generate revenue of $419.5 Million till 2026. Amongst these regions, the Asia-Pacific region is anticipated to be the fastest-growing region for cancer stem cells market. Governing bodies of India, Japan, and other countries are promoting Stem cell transplant by constructing new infrastructure and enlisting new strategies for the launch of centers of stem cells.

The major players in the global cancer stem cell market are introducing several strategies to reinforce their presence in the market

Get Access to Full Report (TOC, Figures, Chart, etc.) @ https://www.researchdive.com/32/cancer-stem-cells-market

Segmentation Growth Definition of Cancer Stem Cells Market:

Breast cancer market will surpass $295.0 million in the year 2026, and is anticipated to rise at 10.4% CAGR during the estimate period. The cancer stem cells market for bladder is anticipated to increase at 11.2% CAGR, and will surpass $275.8 million by 2026, rising from $117.9 million in 2018. Global market for stem cell based cancer therapy was $440.3 million by end of 2018 and is anticipated to grow at 9.3% CAGR. This is majorly due to the rising advancements in stem cell therapy of Asia-Pacific and Europe region.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

Originally posted here:
Global cancer stem cells market is projected to reach up to $896.9 million by the end of 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

View original post here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

Recommendation and review posted by Bethany Smith

The research report by The Insight Partners, titled, Cell Therapy Market, offers a comprehensive analysis of key growth drivers, key segments, development strategies, market opportunities, and competitive landscape. This study offers detailed insights for market players, investors, stakeholders, and new entrants to understand the industry dynamics and determine strategic steps to gain a competitive advantage.

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is used to treat a variety of blood cancers and blood-related conditions.

Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00009666/

Major Players Included in this report are as follows

Kolon TissueGene, Inc. MEDIPOST JCR Pharmaceuticals Co. Ltd. Stemedica Cell Technologies, Inc. Osiris Therapeutics, Inc. NuVasive, Inc. Fibrocell Science, Inc. Vericel Corporation Cells for Cells Celgene Corporation

Cell Therapy Market: Regional analysis includes:

This report on Cell Therapy Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Cell Therapy Market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters. The study is ubiquitous of the major insights related to the regional spectrum of this vertical as well as the companies that have effectively gained a commendable status in the Cell Therapy Market.

The global cell therapy market is segmented on the basis of therapy type, product, technology, application, end user. Based on the therapy type the market is classified as autologous, and allogeneic. Based on product the market is segmented as equipment, consumables, software and services. Based on technology the market is segmented as somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Based on application the market is classified as oncology, cardiology, orthopedic, wound management and others. And based on end user the market is divided into hospitals, regenerative medicine centers, and research institutes.

The Cell Therapy Market research covers an exhaustive analysis of the following data:

Historical and future growth of the global Cell Therapy Market.

Segmentation of the Cell Therapy Market to highlight the growth prospects and trends impacting these segments.

Changing consumption behavior of customers across various regions.

Regional analysis on the basis of market share, growth outlook, and key countries.

Agreements, product launches, acquisitions, and R&D projects of different Cell Therapy Market players.

The Cell Therapy Market research addresses critical questions, such as

Why is region surpassing region in terms of value by the end of 2027?

How are the consumers using Embolization Devices for various purposes?

Which players are entering into collaborations in the market of the Embolization Devices?

At what rate has the global Cell Therapy Market been growing throughout the historic period?

In terms of value, which segment holds the largest share?

Purchase Copy of This Report at:https://www.theinsightpartners.com/buy/TIPRE00009666/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

Follow this link:
Cell Therapy Market Top Manufacturers, Industry Size, Challenges, Drivers, Countries, And Technology Forecast To 2027 | Stemedica Cell Technologies,...

Recommendation and review posted by Bethany Smith

The frenetic search for the miracle that will rid the world of COVID-19 is branching out in a thousand directions, and a large part of the microbial treasure hunt is going on in the Bay Area, where major progress has been made in the 100 days since residents were ordered to shelter in place.

Scientists at universities, laboratories, biotechnology companies and drug manufacturers are combing through blood plasma taken from infected patients for secrets that will help them fight the disease.

The key is likely a super-strength antibody found in some patients. But researchers must first figure out how those antibodies work and how they can be harnessed and used to stop the many health problems associated with COVID-19, particularly acute respiratory distress syndrome, or ARDS, which has killed more people than any other complication connected to the disease.

Other developments showing promise include injections of mesenchymal stem cells, found in bone marrow and umbilical cords, that doctors are studying to battle inflammation caused by ARDS. And a steroid called dexamethasone reduced the number of deaths by halting the overreactive immune responses in seriously ill patients in the United Kingdom.

In all, more than 130 vaccines and 220 treatments are being tested worldwide.

What follows is a list of some of the most promising elixirs, medications and vaccines with ties to the Bay Area:

Monoclonal antibodies / Vir Biotechnology, San Francisco: Scientists at Vir and several institutions, including Stanford and UCSF, are studying monoclonal antibodies, which are clones of coronavirus-fighting antibodies produced by COVID-19 patients.

The idea is to utilize these neutralizing antibodies which bind to the virus crown-like spikes and prevent them from entering and hijacking human cells.

Only about 5% of coronavirus patients have these super-strength antibodies, and those people are believed to be immune to a second attack.

The trick for scientists at Vir is to identify these neutralizing antibodies, harvest, purify and clone them. If they succeed, the resulting monoclones could then be used to inoculate people and it is hoped give them long-term immunity against the coronavirus. The company recently signed a deal with Samsung Biologics, in South Korea, to scale up production of a temporary vaccine in the fall after clinical trials are complete.

Another monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn. The companys chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Interferon-lambda / Stanford University: Doctors at Stanford are running a trial to see if interferon-lambda, which is administered by injection, helps patients in the early stages of COVID-19. Interferon-lambda is a manufactured version of a naturally occurring protein that has been used to treat hepatitis. Stanford doctors hope it will boost the immune system response to coronavirus infections.

Dr. Upinder Singh, a Stanford infectious-disease expert, said the trial has enrolled more than 50 patients and is halfway finished. We have noted that patients tolerate the drug very well, she said.

Mesenchymal stem cells / UCSF and UC Davis Medical Center: UCSF Dr. Michael Matthay is leading a study about whether a kind of stem cell found in bone marrow can help patients with ARDS. Matthay hopes that the stem cells can help reduce the inflammation associated with some of ARDS most dire respiratory symptoms, and help patients lungs to recover.

Matthay is aiming to enroll 120 patients in San Francisco, the UC Davis Medical Center in Sacramento and hospitals in a handful of other states. He said the trial, which includes a small number ARDS patients who dont have COVID-19, should have results within a year. So far 17 patients are enrolled in the trial, most of them in San Francisco.

Remdesivir / Gilead Sciences (Foster City): Remdesivir, once conceived as a potential treatment for ebola, was the first drug to show some promise in treating COVID-19 patients. The drug interferes with the process through which the virus replicates itself. A large study led by the federal government generated excitement in late April when officials said hospitalized patients who received remdesivir intravenously recovered faster than those who received a placebo.

A later study looking at dosage showed some benefit for moderately ill COVID-19 patients who received remdesivir for five days, but improvement among those who got it for 10 days was not statistically significant. Gilead, a drug company, recently announced that it will soon launch another clinical trial to see how remdesivir works on 50 pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. More than 30 locations in the U.S. and Europe will be involved in the trial, the company said.

Coronavirus crisis: 100 days

Editors note: Its been 100 days since the Bay Area sheltered in place, protecting itself from the coronavirus pandemic. What have we learned in that time? And what does the future hold for the region and its fight against COVID-19? The Chronicle explores the past 100 days and looks to the future in this exclusive report.

Favipiravir / Fujifilm Toyama Chemical (Stanford University): This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a Stanford University trial that began this month. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

Stanford epidemiologists want to see if favipiravir, which has shown promising results in other trials, prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. The Stanford study, the only outpatient trial for this drug in the nation, is enrolling 120 people who have been diagnosed with COVID-19 within the past 72 hours. Half of them will get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Colchicine / UCSF (San Francisco and New York): The anti-inflammatory drug commonly used to treat gout flare-ups is being studied in the U.S. by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the bodys production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19. About 6,000 patients are receiving colchicine or a placebo during the clinical trial, dubbed Colcorona, which began in March and is expected to be completed in September.

Selinexor / Kaiser Permanente: Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing, as a potential COVID-19 treatment. The drug has both antiviral and anti-inflammatory properties, and its administered orally, according to Kaisers Dr. Jacek Skarbinski. The trial aims to enroll 250 patients with severe symptoms at Kaiser and other hospitals that are participating nationwide.

VXA-COV2-1 / Vaxart, South San Francisco: The biotechnology company Vaxart is testing this drug to see if it is as effective at controlling COVID-19 as trials have shown it to be against influenza. VXA-COV2-1, the only potential vaccine in pill form, uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

Its the only vaccine (candidate) that activates the first line of defense, which is the mucosa, said Andrei Floroiu, Vaxarts chief executive, noting that intravenous vaccines kill the virus after it is inside the body. Our vaccine may prevent you from getting infected at all.

The drug was effective against influenza and norovirus in trials and appears to work on laboratory animals, Floroiu said. He expects trials of VXA-COV2-1 on humans to begin later this summer.

VaxiPatch / Verndari (Napa and UC Davis Medical Center): Napa vaccine company Verndari makes a patented adhesive patch that can deliver a vaccine instead of a shot. Now, the company is trying to make a vaccine for COVID-19 that they can administer through that patch. At UC Davis Medical Center in Sacramento, Verndari researchers are developing a potential vaccine that relies on the coronavirus spike-shaped protein. When injected into a person, the substance would ideally train their body to recognize the virus and fight it off without becoming ill.

A spokeswoman told The Chronicle that the companys preclinical tests have shown early, positive data in developing an immune response. Verndari hopes to move into the next phase of testing in the coming weeks and start clinical trials in humans this year.

If the vaccine is proved effective and safe, patients could receive it through the mail, according to company CEO Dr. Daniel Henderson. The patch would leave a temporary mark on the skin that patients could photograph and send to their doctor as proof they have taken the vaccine, Henderson has said.

Peter Fimrite and J.D. Morris are San Francisco Chronicle staff writers. Email: pfimrite@sfchronicle.com, jd.morris@sfchronicle.com Twitter: @pfimrite, @thejdmorris

Go here to read the rest:
Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle

Recommendation and review posted by Bethany Smith

Whoever would have thought that the turn of a new decade would bring such a cataclysmic event to our world? Our economy was humming along. Times were good, and business was booming. Then along comes a pestilence in the form of a microscopic virus that has shaken our world to its core.

Tens of thousands of Americans have died. Hundreds of thousands have become ill. Millions have lost their jobs. And tens of millions have been isolated and socially distanced from friends and loved ones. History will look back on the Covid-19 pandemic as a turning point in our lives.

And while all of this has been going on, manufacturers continue to produce goods, warehouses process orders, trucks roll and deliver, and supply chains continue to function.

It has not been without a hitch, but supply chain has certainly been among the few bright spots during the pandemic. Finally, every American is aware of what supply chain professionals do each and every day without fanfare. Warehouse workers and drivers continue to show up for work, risking their health and their emotional well-being to keep freight moving.

In the following stories, we salute some of the many individuals and companies who have used their talents and resources to bring healing and hope, deliver comfort, and save lives during the Covid-19 crisis. We thank these unsung heroes who have quietly gone about their work to make sure the rest of us have what we need to make life appear almost normal.

Click one of the headlines below to skip ahead to a particular story.

Back to index

Stepping up their use of technology is one of the many ways logistics firms are meeting volatile business conditions brought on by the Covid-19 pandemic. Fort Wayne, Indiana-based Circle Logistics and White Plains, New York-based Capital Logistics are two examples of companies digging deeper into visibility tools to help monitor and manage freight shipments, especially for critical food and medical supply chains.

Both companies said this spring they were using Descartes Systems Groups MacroPoint real-time freight visibility solution to track critical loads for customers such as the Federal Emergency Management Agency (FEMA) and major grocery brands. Circle Logistics said it shifted its entire transportation network to manage a 700% increase in volume from customers moving critical freight, including personal protective equipment (PPE), respirators, cots for FEMA, and grocery loads. Company leaders said the platform allows it to better track the movement of goods under volatile conditions.

At Capital Logistics, leaders are also integrating Descartes Aljex cloud-based transportation management system (TMS) to manage volatility. Designed for freight brokers, the system automates planning, freight tendering, and dispatching as well as back-office functions including accounting, invoicing, and reporting. The integration with MacroPoint provides real-time freight visibility to automatically track loads, greatly reducing the manual efforts for track-and-trace teams, according to Descartes.

As our customers focus on keeping food supply chains functioning, having real-time visibility into the status of critical freight has increased our ability to keep pace with the unpredictable demand grocery stores are experiencing, Greg Ackner, vice president at Capital Logistics, said in late April. In one case, we went from moving two to three truckloads of milk per week to distribution centers serving multiple states to 50 to 60 truckloads per week.

Back to index

Forklift vendor Combilift is stepping up to address the shortage of medical equipment for treating Covid-19 patients by developing a splitter device that turns one ventilator into multiple ventilation stations.

Monaghan, Ireland-based Combilift used its resources in engineering and software design to pivot from the material handling sector to create the Combi-Ventilate, saying the unit will address the requirements of medical professionals in the Covid-19 emergency.

The Combi-Ventilate uses standard pipes and fittings for easy assembly, offers individual patient filters that prevent cross contamination, and supports dedicated computer screens for each patients vital information. The device is designed as an attachment that can be added to any brand of ventilator, installed easily into a hospitals intensive care unit (ICU), and purchased for a fraction of the cost of a standard ventilator, the firm said.

Back to index

The International Foodservice Distributors Association (IFDA) and FMI-Food Industry Association are partnering to help keep store shelves stocked amid the coronavirus pandemic. In March, the groups announced a partnership that aims to match food-service distribution companies that have excess product, warehouse space, and transportation capacity with food retailers and wholesalers in need of assistance, the associations said.

The partnership addresses the issue of excess product and capacity caused by the closing of restaurants, schools, and other businesses with retailers and wholesalers seeking to replenish store shelves more quickly. IFDA and FMI are gathering information from their members and matching capacity to need geographically, essentially functioning as a clearinghouse for contact information, according to IFDA spokeswoman Meghan Cieslak. She emphasized that the program aims to help fill demand for products but will also help fill demand for trucks, drivers, warehouse staff, warehouse storage, and similar needs.

Back to index

The Illinois-based material handling equipment dealer MH Equipment has used its corporate charity program to support several initiatives during the economic shutdowns and shortages caused by the Covid-19 pandemic.

First, the firm launched a campaign to address food shortages faced by community food banks and pantries during the coronavirus emergency. The companys Purpose Unites program allows employees to automatically deduct part of their paychecks to support local food banks. Along with donations from the companys His First Foundation charitable program, the effort raised nearly $187,000 across 33 office locations in just four days.

Second, the companys charity arm paid many of MH Equipments own employees to perform volunteer community service, using spare time they had available due to a drop in demand during the recession. MH Equipment compensated them for more than 4,000 hours of volunteer community service time across several Midwest states throughout the month of April. Those tasks included helping food banks with loading/unloading trucks, meal delivery, and packaging; making masks; mowing yards for the elderly and for nonprofit organizations; and using their technical skills to assist with light mechanical work on fire engines at volunteer fire departments.

Back to index

Truck drivers moving in and out of hot zones to perform essential work are receiving personal protective equipment (PPE) thanks to a collaboration between DDC FPO, a back-office partner for the transportation industry, and Truckers Emergency Assistance Responders (TEAR), a 501c3 nonprofit organization founded with the mission to help truck drivers in distress.

TEAR has built and deployed a network of corporate sponsors and volunteers to source, assemble, and distribute PPE kits to truck drivers on the front lines. Delivered at truck stops and rest areas, each PPE kit includes masks, hand sanitizer, gloves, antiseptic wipes, and snacks. The drivers are so appreciative, TEAR leader Desiree Wood said. They spend all day by themselves and arent used to receiving anything for free, let alone being recognized. They are thrilled to receive the kits.

Back to index

Supply chain technology provider Trimble Inc. has launched a free web app that displays truck-stop status and amenity information, allowing truck drivers to find essential break locations, showers, and restaurants.

The information comes as many break locations have closed completely or have shuttered certain amenities during the coronavirus crisis. Currently available on desktop or mobile devices in North America only, the Covid-19 Safe Haven Web App is intended to help the transportation community find out which locations are closed and which conveniences are open. Drivers can also use the platform to find Walmart locations with overnight parking, view live traffic and weather reports, and help their peers by reporting location closings.

Back to index

E-commerce retailer Amazon.com Inc. has teamed up with medical device manufacturer Boston Scientific to deliver donated face shields to health-care facilities around the U.S. fighting the Covid-19 pandemic.

Health-care volunteer coalition GetUsPPE organized the effort, under which Boston Scientific mobilized employees at a dozen sites to produce and donate the personal protective equipment (PPE), while Amazon offered logistics support. Amazon provided space on its trailers to deliver the shields from Boston Scientific to local delivery stations, where Amazon associates have worked with delivery service partners in Chicago, Detroit, and the Washington, D.C./Baltimore metro areas to deliver the face shields to hospitals and clinics.

Back to index

Job training nonprofit group Goodwill of South Florida has converted a portion of its sewing operations to manufacture 20,000 masks for employees at transportation and logistics company Ryder System Inc. The initiative extends a long relationship between the two organizations, since company founder James Ryder was also one of three founders of Goodwill some 60 years ago, David Landsberg, CEO of Goodwill of South Florida, said in a release.

The masks are being used to protect Ryders essential employees as they support the flow of goods and services needed in the fight against Covid-19. Each mask is made with camouflage material on the outside, a softer fabric on the inside, and elastic ear loops.

Back to index

Automaker Kia Motors America is donating personal protective equipment (PPE) to hospitals and medical facilities during the Covid-19 crisis. The face shields are assembled at its Kia Motors Manufacturing Georgia plant in West Point, Georgia, and the brand plans on donating a total of 300,000 face shields nationwide.

A group of company volunteers called Telluriders recently delivered face shields to Morristown Medical Center/Atlantic Health in Morristown, New Jersey. The deliveries were part of Kias Accelerate the Good initiative, which includes ongoing face shield donations to medical facilities in New Jersey, Southern California, and Georgia.

Back to index

Beer maker Sierra Nevada Brewing has donated some of its food laboratory resources in Chico, California, to making a critical component used in tests for detecting Covid-19 infections.

Sierra Nevada is using its quality assurance labusually dedicated to testing beer for unwanted bacteria and wild yeastfor creating the viral transport medium that is in short supply for enabling coronavirus tests. The medium is used to protect the swab that doctors insert into patients nostrils while it is transferred to a medical lab. In this case, the beer maker has already delivered 1,000 vials of the liquid to Californias Enloe Medical Center and is planning to make up to 10,000 more.

Back to index

Employees at Jacksonville, Florida-based third-party logistics service provider (3PL) Atlantic Logistics have started a bulk hand sanitizer rebottling program that will serve local truck drivers. In April, employees partnered with TravelCenters and TA-Petro to set up personal distribution of hand sanitizer and masks to drivers at their truck stop at I-10 and U.S. Highway 301 in Jacksonville.

Most Americans want to give back and say Thank you to the truckers that keep the shelves stocked and the country moving, Rob Hooper, Atlantic Logistics CEO, said in a statement. Im so proud of the initiative our employees took to help make these folks lives a little safer and simpler.

Back to index

Volunteers from the North American technology community have banded together to build a mobile app that helps truck drivers find essential services near their current locations, so they can continue operating safely during the Covid-19 pandemic.

Known as Truckers Welcome, the site serves as a social application that lets businesses add and share information about the services they are still able to provide to driverssuch as drive-through meals, washrooms, Wi-Fi, and fuel. With over 1,600 locations registered across the U.S. and Canada since it launched, the site addresses some of the significant challenges truck drivers face while on the road keeping goods and supplies flowing to grocery stores, hospitals, and communities, its creators say.

Back to index

Third-party logistics service provider (3PL) Logistics Plus Inc. provided free customs clearance and delivery services to transport a load of 50,000 surgical masks for the city of Erie, Pennsylvania.

The masks were originally donated by Eries sister city, Zibo, China, and airfreighted to Chicago. Erie-based Logistics Plus then facilitated the customs clearance and paperwork, took possession of the shipment, and arranged complimentary transportation of the goods from Chicago to Erie.

Together we are Erie Strong, Jim Berlin, founder and CEO of Logistics Plus, said in a release. Helping [Erie] Mayor [Joe] Schember and the city get these masks from Chicago to Erie and in the hands of our front-line government workers was an easy decision. It feels good to donate and to do something for those in need.

Back to index

The Raymond Corp. put its weight into the Covid-19 fight to help local health-care workers and first responders. The New York-based maker of forklifts and other material handling equipment and solutions used its engineering might to 3D print and assemble face shields at its Greene, New York, facility. Company President and CEO Mike Field said in April that Raymond would produce 2,000 face shields to be distributed to local hospitals and first responders.

Like everyone, we at Raymond have heard the appeals for protective equipment from our local health-care workers battling the Covid-19 pandemic, Field said in a release. Raymond has the ability and desire to utilize our vast production capabilities to support those crucial employees. ... We will continue to monitor the evolving situation to determine how best we can support our local health-care heroes.

Back to index

Supply chain technology and risk management firm Resilinc responded early to increased demand for critical health-care supplies by launching the The Exchange at Resilinc, an online clearinghouse designed to match available inventory with hospitals that need items, including personal protective equipment, to fight the Covid-19 pandemic. The company announced the initiative March 25, and the exchange was up and running by mid-April.

Resilinc partnered with representatives from the health-care and logistics sectors to create the exchange, which will allow group purchasing organizations (GPOs), distributors, and hospitals to connect and exchange inventory and to access donated inventory from manufacturers and other organizations. The program is designed to digitize and broaden a system that is largely done informally and manually between trading partners. The exchange will be free for all U.S. hospitals through September, according to Resilinc Founder and CEO Bindiya Vakil.

Back to index

The American Trucking Associations (ATA) joined with corporate partners to further its #thankatrucker campaign, launching its Providing for the Frontlines initiative in May.

Insurance provider OneBeacon, U.S. Bank, Michelin, and Hydro-Chem Systems are partnering with ATA to provide hand sanitizer nationwide as well as meals for professional truck drivers on the road, the groups said.

This new initiative aims to celebrate unsung heroes in the trucking industry who continue to bravely deliver Americas goods throughout the ongoing coronavirus pandemic, as well as provide relief to the hard-working men and women behind the wheel, Arlington, Virginia-based ATA said in a statement.

The initiative will include a photo contest in which drivers can submit a fun photo of themselves and their rig. Once submitted, they will be entered into a drawing to win a $25 electronic gift card for a meal of the drivers choice while on the road. Multiple winners will be selected daily. Truckers can enter and anyone can view the daily winners at http://www.trucking.org/thankatrucker.

Providing for the Frontlines builds on ATAs efforts to support truckers nationwide. Also in May, the association teamed up with Protective Insurance and ABF Freight to supply 550 gallons of hand sanitizer to eight states across the country. By mid-month, thousands of drivers had been able to refill their personal supply at no cost to them, ATA said.

Back to index

Logistics robot technology provider Brain Corp. is donating $1.6 million worth of autonomous floor-cleaning robots and services to essential businesses during the Covid-19 pandemic.

Autonomous mobile robots (AMRs) are playing a vital role in helping support essential businesses and their workers on the front lines of the health crisis, since retailers, airports, and hospitals are required to clean more frequently and deliver more cleaning coverage than usual. Autonomous floor scrubbers powered by Brain Corp.s BrainOS software are providing more than 8,000 hours of daily workequal to a quarter-million hours throughout the month of Maythat otherwise would have to be done by an essential worker, the company said.

Back to index

Transport and logistics firms Gebrder Weiss and Delta Group Logistics teamed up to deliver thousands of pieces of personal protective equipment (PPE) to health and safety workers in the Chicago area as they continued to fight the Covid-19 pandemic in May.

The companies purchased and distributed 8,000 face masks and 1,000 face shields to various organizations and companies in Chicago and the surrounding suburbs. A majority of the face shields donated went directly to Springfield, Illinois, to help stock the Centers for Medicare & Medicaid Services state surplus warehouse so that shields are ready when they are needed, the companies said.

The companies planned to continue donating PPE throughout the month.

Separately, Illinois-based Seko Logistics has stepped up its own PPE efforts with donations for front-line workers and by providing additional equipment for its own essential workforce, the company said.

As of mid-May, Seko Logistics had distributed more than 28,000 face masks and 138,000 gloves to its front-line teams in North America along with additional PPE kits for its MedTec drivers, which support medical deliveries nationwide. That comes on top of a pledge to donate $200,000 for the purchase of PPE for health-care workers treating Covid-19 patients around the country.

Back to index

Liquid and powder coatings supplier Axalta has shifted the manufacturing capabilities of its facility in Tlalnepantla, Mexico, to produce more than 1,000 liters (264 gallons) of hand sanitizer, which is being donated to local health-care facilities, first responders, and other essential businesses.

These efforts complement Axaltas global support of coronavirus relief efforts, which include sending personal protective equipment (PPE) to hospitals in the U.S., France, Belgium, and Germany, and providing more than 5,000 seat covers to medical professionals, who can use the seat covers in their own cars to reduce the risk of transmitting the coronavirus when they are visiting those infected with the virus.

Back to index

Aerospace and defense contractor Lockheed Martin Corp. has donated cargo capacity on its corporate aircraft as an in-kind donation to support the federal governments Covid-19 response for medical transplants, helping ensure that the life-saving products from European donors reach American patients on time.

The flights help ensure the timely delivery of bone marrow and blood stem cells for transplant, a need that arose when the National Marrow Donor Program (NMDP)/Be The Match ran out of available European Union couriers to deliver life-saving cells to U.S. patients, since tens of thousands of commercial flights had been canceled during the pandemic. Lockheed Martin will be providing weekly air transport based on government medical needflying government medical teams to the most critical, high-priority locations around the country and/or flying to support bone-marrow transport to help with the governments coronavirus response.

Back to index

Chocolate maker The Hershey Co. has committed $1 million to acquire, install, and staff a new manufacturing line dedicated to the production of face masks during the Covid-19 emergency.

Leveraging its internal engineering capabilities and its relationships with equipment manufacturer JR Automation and General Motors, which is making similar masks, the company is moving quickly to address the nationwide shortage of protective equipment. When it becomes operational, the Hershey, Pennsylvania-based line will be capable of producing up to 45,000 masks per day, the company said in mid-May.

Back to index

Transportation and logistics services provider DHL Global Forwarding, packaging and design venture Royal Bay, and tracking technology firm LocatorX have stepped up to provide personal protective equipment (PPE) and other services to front-line workers.

DHL Global Forwarding is partnering with customers in the health-care industry to ship more than 100 tons per week of medical supplies, equipment parts, pharmaceuticals, and protective clothing for hospitals, health-care workers, and patients throughout the United States and is also offering special charters to and from China to ease the capacity crunch for customers, officials said in May.

Royal Bay, a joint venture between packaging and design companies Bay Cities and The Royal Group, is assembling and packaging 2 million face shields for essential workers. The shields will be distributed to medical suppliers and distributors, who will send them to medical facilities and hospitals nationwide. At capacity, Royal Bay will assemble and package 500,000 units per week, the companies said.

Atlanta-based tracking technology firm LocatorX has launched a National Medical Device Registry allowing hospitals to log their life-saving equipment at no cost during the Covid-19 crisis. The registry will also help hospitals quickly and easily identify the status of venilators available for loan, the company said.

Read more:
Heroes of the Supply Chain | 2020-06-25 - DC Velocity

Recommendation and review posted by Bethany Smith

The Cell Therapy Manufacturing Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Cell Therapy Manufacturing market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Cell Therapy Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Cell Therapy Manufacturing report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The research report also focuses on global major leading industry players of Cell Therapy Manufacturing market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Cell Therapy ManufacturingMarket Key Companies:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

The predictions mentioned in the Cell Therapy Manufacturing market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

The report provides an in-depth analysis of the Cell Therapy Manufacturing market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622

Continued here:
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 - 3rd Watch News

Recommendation and review posted by Bethany Smith

A clinical trial examines the emotional impact of at-home genetic testing for cancer, when pre-test counseling is skipped.

PORTLAND, Ore. There are DNA tests available for people to take at home to learn if theyre at high risk for developing certain cancers. For women, that includes ovarian cancer. But is it a good idea, emotionally, to use an at-home test to get potentially life-altering information?

A recent clinical trial set out to answer that question. The trial is called MAGENTA, which stands for Making GENetic Testing Accessible. It was sponsored by Stand Up to Cancer, the Ovarian Cancer Research Alliance and the National Ovarian Cancer Coalition.

The clinical trial involved nearly 4,000 women from across the country. They were asked to test for the most serious cancer-causing gene mutations using a saliva-based test kit at home. Researchers then studied the results of different combinations of remote pre and post-test genetic counseling for cancer risk. The trial concluded that genetic testing can be provided remotely and that genetic counseling before and after testing can be skipped without causing increased distress to patients.

We weren't sure if it was safe to be testing this way, said Dr. Elizabeth Swisher, a co-leader of the Stand Up to Cancer Dream Team and based out of the University of Washington. She said the trial also showed that participants who were required to have pre-test counseling were less likely to complete the process. She said that's key, since their goal is getting more women tested for ovarian cancer, which is hard to detect before it spreads. Doctors note women with the BRCA1 BRCA2 gene mutations were 20 to 40% more likely to develop breast and ovarian cancer than those without it.

That risk doesn't go away if you hide your head in the sand, but if you know that information then you can do something about it and change outcomes, said Swisher. Ultimately, if we're going to catch this risk, we can't just target this testing towards women with a strong family history; we really need to do it at a population level.

Stand Up to Cancer teamed up with Color Genomics for the trial. The genetic testing company offers a similar test to the public now for $249 which includes post-results counseling. Many insurance providers will offset the cost for patients with an applicable family history of cancer.

Portland oncology nurse Tricia Laine participated in the clinical trial after learning about it at a medical conference.

My grandmother died of ovarian cancer when she was 52, when my mother was in college, said Laine, 34. Its always been something that's been in our family history.

Laine said despite the convenience of the test, choosing to take it was a decision she approached thoughtfully.

I had to ask my family first if it was OK that I did this, said Laine. Because it would tell us a lot of information.

Laines test results came back negative, though she doesnt believe it means her future is necessarily clear of cancer. She said she will use the test result knowledge as power, and hopes others will do the same.

I don't think you should not [take the test] out of fear.

See the original post:
'That risk doesn't go away if you hide your head in the sand': New study validates at-home DNA tests for cancer risk - KGW.com

Recommendation and review posted by Bethany Smith

NICE has publisheddraft recommendationson testing for Lynch syndrome in people with endometrial cancer.

The draft guidance recommends testing for Lynch syndrome in people with endometrial cancer. The following tests are recommended:

Immunohistochemistry (IHC) testing to identify tumours with mismatch repair (MMR) deficiency.

MLH1 promoter hypermethylation testing of tumour DNA, if IHC is positive.

If MLH1 promoter hypermethylation test is negative, confirm Lynch syndrome by genetic testing of germline DNA.

Genetic testingcan also be offered to relatives with the aim of preventing Lynch syndrome-associated cancer developing or detecting it at an early stage. Discussions about genetic testing should be done by a healthcare professional with appropriate training.

While testing for Lynch syndrome is recommended after a diagnosis of colorectal cancer, endometrial cancer is often the first cancer that people with Lynch syndrome develop. NICE says Lynch syndrome could be identified earlier if tests were done after a diagnosis of endometrial cancer.

Economic modelling has shown that IHC testing then MLH1 promoter testing is likely to be the most cost-effective approach. If it looks like a person may have Lynch syndrome after both tumour tests have been done, genetic testing of non-tumour DNA should be done to confirm this.

The draft recommendations are open forconsultationuntil 13 July.

This article originally appeared on Univadis, part of the Medscape Professional Network.

Follow this link:
NICE Guidance on Testing for Lynch Syndrome in People with Endometrial Cancer - Medscape

Recommendation and review posted by Bethany Smith

Theglobal direct-to-consumer genetic testing marketis primarily segmented based on different technology, test type, distribution channel and region.

On the basis technology, market is segmented into targeted analysis, single nucleotide polymorphism (SNP) chips, and whole genome sequencing (WGS).

Direct-to-Consumer Geneticprovides people access to their genetic information without necessarily involving a healthcare provider or health insurance company in the process.

These genetic tests are marketed directly to customers via television, print advertisements, or the Internet, and the tests can be bought online or in stores.

Get Sample Copy of this Report @https://www.orianresearch.com/request-sample/1261431

Direct-to-Consumer Genetic Testing Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Market Segment by Manufacturers:

Ancestory 23andMe, Color Family Tree DNA EasyDNA Helix Indentigene Full Genomes Genesis HealthCare .

Report Covers Market Segment by Types:

Carrier Testing Predictive Testing Ancestory & Relationship Testing Nutrigenomics Testing Other Testing

Global Direct-to-Consumer Genetic Testing Industry 2019 Market Research Report is spread across 114 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report 2019 @https://www.orianresearch.com/checkout/1261431

Report Covers Market Segment by Applications:

Targeted Analysis Single Nucleotide Polymorphism (SNP) Chips Whole Genome Sequencing (WGS)

Key Benefits of the Report:

Global, and regional, product type & application market size and their forecast from 2019-2026 Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing the growth of the market

Detailed analysis on industry outlook with market specific PEST analysis, and Supply Chain to better understand the market and build expansion strategies Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points Analysis on key players strategic initiatives and competitive developments, such as agreements & joint ventures, mergers & acquisitions, expansion, and new product launches in the market Expert interviews and their insights on market trends, market shift, current and future outlook, and factors impacting vendors short term & long term strategies Detailed insights on emerging regions, product type and application with qualitative and quantitative information and facts Identification of the key patents filed in the field of Direct-to-Consumer Genetic Testing equipment and other related technologies.

Target Audience:

Direct-to-Consumer Genetic Testing providers Traders, Importer and Exporter Raw material suppliers and distributors Research and consulting firms Government and research organizations Associations and industry bodies

Inquire more about Direct-to-Consumer Genetic Testing Market report @https://www.orianresearch.com/enquiry-before-buying/1261431

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with theKey Industry Participants (KIPs) which typically include:

Original Equipment Manufacturer Component Supplier Distributors Government Body & Associations Research Institute

Table of Content

1 Executive Summary2 Methodology And Market Scope3 Direct-to-Consumer Genetic Testing Market Industry Outlook4 Direct-to-Consumer Genetic Testing Market By End User5 Direct-to-Consumer Genetic Testing Market Type6 Direct-to-Consumer Genetic Testing Market Regional Outlook7 Competitive LandscapeEnd of the report

Disclaimer

Customization Service of the Report:Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (832) 380-8827 | UK: +44 0161-818-8027Email:[emailprotected]Website: http://www.orianresearch.com/

Original post:
COVID-19 Impact on Global Direct-to-Consumer Genetic Testing Industry 2020: Industry Trends, Size, Applications, SWOT Analysis by Top Key Players and...

Recommendation and review posted by Bethany Smith

The report provides an exhaustive calculation of the Breast Cancer Predictive Genetic Testing comprising of industry chain structure, market drivers, opportunities, future roadmap, industry news analysis, industry policy analysis, market player profiles and strategies. The report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures.

Complete report on Breast Cancer Predictive Genetic Testing market spread across 142 pages, profiling companies and supported with tables and figures is now available @ https://www.insidemarketreports.com/sample-request/10/370072/Breast-Cancer-Predictive-Genetic-Testing

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

With tables and figures helping analyze worldwide Breast Cancer Predictive Genetic Testing market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Companies profiled and studied for this Breast Cancer Predictive Genetic Testing market report include Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae and others.

The report is based upon arduous data analysis carried out by industry doyens. The all-inclusive analysis of these data provides an in-depth and detailed insight into the global Breast Cancer Predictive Genetic Testing market. The report further provides the new and existing players with information such as company profiles, facts and figures, product picture and specifications, sales, market share and contact information.

Major Points covered in this report are as below

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase the copy of this report at: https://www.insidemarketreports.com/buy-now/10/370072/Breast-Cancer-Predictive-Genetic-Testing/single

Purchase this Report now by availing up to 40% Discount and free consultation.Offer is valid for June 2020 only.

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Original post:
How Corona Pandemic will impact Breast Cancer Predictive Genetic Testing market and what change Development Strategy 2020-25 - Cole of Duty

Recommendation and review posted by Bethany Smith

The globalDirect-to-Consumer (DTC) Genetic Testing Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Direct-to-Consumer (DTC) Genetic Testing market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Direct-to-Consumer (DTC) Genetic Testing market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Direct-to-Consumer (DTC) Genetic Testing market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Direct-to-Consumer (DTC) Genetic Testing market.

Leading players of the global Direct-to-Consumer (DTC) Genetic Testing market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Direct-to-Consumer (DTC) Genetic Testing market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Direct-to-Consumer (DTC) Genetic Testing market. It also provides useful recommendations for new as well as established players of the global Direct-to-Consumer (DTC) Genetic Testing market.

Request sample copy of this report:https://www.reporthive.com/request_sample/2292341

Major Players:

23andMedeCODEmeDNA DTCGeneByGeneGenecodebook OyGenetrainerMD RevolutionMyriad GeneticsNavigenics

Segmentation by Product:

Genome Data Bank Material ModelIndividual Health Planning ModelComprehensive Genome Tests ModelMedical Precision Tests ModelRestricted Trait Tests Model

Segmentation by Application:

Doctor OfficeInternetOthers

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

Table of Contents

Report Overview:It includes major players of the global Direct-to-Consumer (DTC) Genetic Testing market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Direct-to-Consumer (DTC) Genetic Testing market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Direct-to-Consumer (DTC) Genetic Testing market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Direct-to-Consumer (DTC) Genetic Testing market by application, it gives a study on the consumption in the global Direct-to-Consumer (DTC) Genetic Testing market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Direct-to-Consumer (DTC) Genetic Testing market are profiled in this section. The analysts have provided information about their recent developments in the global Direct-to-Consumer (DTC) Genetic Testing market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Direct-to-Consumer (DTC) Genetic Testing market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Direct-to-Consumer (DTC) Genetic Testing market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Direct-to-Consumer (DTC) Genetic Testing market.

Key Findings:This section gives a quick look at important findings of the research study.

Request for Customization:https://www.reporthive.com/request_customization/2292341

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

The rest is here:
Impact of Corona on Direct-to-Consumer (DTC) Genetic Testing Market Key Manufactures and Business Overview till 2026 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Adults under 40 who develop cancers that are rare for their age bracket have a high rate of inherited gene mutations associated with cancer.

People with inherited genetic mutations who develop such cancersknown as early-onset cancersare more likely to develop new malignancies unrelated to their first cancer and to experience other health complications.

The most common early-onset cancers, which by definition are rare malignancies among younger adults, are breast, colon, pancreas kidney, prostate and ovarian cancer. These are distinct from other types of cancer that are more commonly seen among young adults, such as sarcoma and brain cancer.

Thus, the new findings from a recent study, presented this week at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, have important implications for how younger adults with cancer might receive genetic counseling that could inform their treatment as well as their ongoing monitoring as they progress through life.

This study supports a role for genetic testing irrespective of tumor types, Zsofia Stadler, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said at an AACR press briefing.

Stadler and her colleagues assessed inherited genetic mutations among 1,201 young adults diagnosed with cancer at Sloan Kettering between 2015 and 2019, looking specifically for up to 88 genes known to be linked to a higher risk of cancer.

Eight hundred seventy-seven of the participants had early-onset cancermost commonly colorectal, breast, kidney, pancreatic and ovarian cancer; 324 had young-adult cancers that are common in this age groupmost commonly sarcoma and brain, testicular and thyroid cancer.

The researchers found that 21% of those with early-onset cancers and 13% of those with young-adult cancers had inherited genetic mutations (also known as germline mutations).

Among people with early-onset cancers, BRCA gene mutations and those associated with Lynch syndrome (the most common cause of hereditary colon cancer) were seen most often. Among those with young-adult cancers, inherited TP53 mutations were more common; these are characteristic of Li-Fraumeni syndrome, which is associated with childhood cancers.

Although they only represent about 4% of all cancers, young adults with cancer, defined as those diagnosed with cancer between the ages of 18 and 39, face unique challenges, said Stadler. Identifying whether a young patients cancer occurred in the setting of an inherited cancer predisposition syndrome is important as it can result in a substantial change in clinical management, such as increased cancer surveillance aimed at early detection and risk-reducing surgery to prevent new cancers and may even have reproductive implications for young families.

To read the study abstract, click here.

To read a press release about the study, click here.

Read this article:
Inherited Genetic Mutations Are Common in Young Adults With Early-Onset Cancer - Cancer Health Treatment News

Recommendation and review posted by Bethany Smith